Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis
about
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.Sick leave and work disability in patients with early arthritisInfliximab for the treatment of ankylosing spondylitis.Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides.Patients with ankylosing spondylitis have increased sick leave--a registry-based case-control study over 7 yrs.Infliximab in the treatment of ankylosing spondylitis.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Variables related to work productivity loss in patients with ankylosing spondylitis.Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden.Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis.Recommendations for the management and treatment of ankylosing spondylitis.Translation into Brazilian Portuguese, cross-cultural adaptation and validation of the Stanford presenteeism scale-6 and work instability scale for ankylosing spondylitis.Centre-related variability in hospital admissions of patients with spondyloarthritis.
P2860
Q35636900-2054257F-BC0A-4856-AC0B-D0734A3DB869Q36166120-740B43F8-5310-445A-8AE2-F621333E4339Q36210882-85CA96B1-F814-4865-99F4-9E24EF0BD78FQ36245711-9E16353B-2041-47A4-A456-DA483B66F4E5Q37100632-E7D7B5A1-F272-49AE-A713-54BCFCE095B5Q37290474-59AE7FA7-44DF-4F89-9ACB-3F2CD599FDF2Q37729028-9867EA96-6200-4918-BB8A-7D81496FCD42Q38139808-385EA0BA-C128-46DA-B047-A7DAC9C46E33Q39033928-26EED8FA-41C4-4793-9FFE-00C63315D746Q40054277-D1134B58-7C66-4897-82A8-642CBC40DC00Q44898441-76C06808-67B8-4FC5-B1A9-9EDC6AA6DE42Q46462893-4EC97F14-049F-4363-8328-C73F22FB89E7Q48177339-DD362064-AB22-44A9-8B40-DFF1C8F581F7
P2860
Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Impact of anti-tumour necrosis ...... ts with ankylosing spondylitis
@ast
Impact of anti-tumour necrosis ...... ts with ankylosing spondylitis
@en
type
label
Impact of anti-tumour necrosis ...... ts with ankylosing spondylitis
@ast
Impact of anti-tumour necrosis ...... ts with ankylosing spondylitis
@en
prefLabel
Impact of anti-tumour necrosis ...... ts with ankylosing spondylitis
@ast
Impact of anti-tumour necrosis ...... ts with ankylosing spondylitis
@en
P2093
P356
P1476
Impact of anti-tumour necrosis ...... ts with ankylosing spondylitis
@en
P2093
P304
P356
10.1136/ARD.2003.017327
P407
P577
2004-12-01T00:00:00Z